Skip to main content

Neuphoria Therapeutics Inc. (NEUP)

Sector
Healthcare
Industry
Biotechnology
Last price
$2.27
As of

Kresmion compiles this page from NEUP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Neuphoria Therapeutics Inc. (NEUP): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-16.

As of . Source: SEC EDGAR filings for NEUP. Method and limitations.

COMPANY DOSSIER

See the full NEUP dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for NEUP on one page. Preview it with sample data, then open it live with a free account.

Preview the NEUP dossier

Active events for NEUP

FREE, NO ACCOUNT

Every event on NEUP, as it fires

You are seeing 5 of 7 events recorded on NEUP since 2026-05-31.

The five above landed across 3 days. The other 2 were recorded on those same days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, NEUP

More data on NEUP

NEUP against its peers

NEUP's operating margin of -1401.1% ranks in the 50th percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricNEUPPeer medianPercentilen
Revenue FY1.2M USD1.0M USD559
Revenue YoY-92.5%n/an/a2
Operating margin-1401.1%-1583.6%508
Net margin-1145.7%-388.3%398
Return on equity-54.7%-114.4%8314
1 year-43.9%-64.1%5616

Peers (18): KYNB, BOLT, MRKR, ALLR, ABOS, MCRB, ACTU, NCEL, HEPA, ATYR, ESLA, INTI, DYAI, CNTX, PLUR, SYBX, AKTX, ADIL. Left out: RADX (no annual filing), CTXR (no annual filing), CKDXF (period gap), HOOK.D (period gap), VICP (period gap), FNCHQ (period gap), QNTM (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NEUP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in NEUP on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on NEUP in the last 180 days.

Upstream: SEC EDGAR filings for NEUP

Kresmion, "Neuphoria Therapeutics Inc. (NEUP) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/NEUP. Upstream data: SEC EDGAR filings for NEUP.

Link to this data (HTML):

<a href="https://kresmion.com/research/NEUP">Neuphoria Therapeutics Inc. (NEUP) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow NEUP on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to NEUP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the NEUP dossier
Share

The NEUP intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.